Luteolin inhibits Cr(VI)-induced malignant cell transformation of human lung epithelial cells by targeting ROS mediated multiple cell signaling pathways

Toxicol Appl Pharmacol. 2014 Dec 1;281(2):230-41. doi: 10.1016/j.taap.2014.10.008. Epub 2014 Oct 23.

Abstract

Hexavalent chromium [Cr(VI)] is a well-known human carcinogen associated with the incidence of lung cancer. Inhibition of metal induced carcinogenesis by a dietary antioxidant is a novel approach. Luteolin, a natural dietary flavonoid found in fruits and vegetables, possesses potent antioxidant and anti-inflammatory activity. We found that short term exposure of human bronchial epithelial cells (BEAS-2B) to Cr(VI) (5μM) showed a drastic increase in ROS generation, NADPH oxidase (NOX) activation, lipid peroxidation, and glutathione depletion, which were significantly inhibited by the treatment with luteolin in a dose dependent manner. Treatment with luteolin decreased AP-1, HIF-1α, COX-2, and iNOS promoter activity induced by Cr(VI) in BEAS-2B cells. In addition, luteolin protected BEAS-2B cells from malignant transformation induced by chronic Cr(VI) exposure. Moreover, luteolin also inhibited the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) and VEGF in chronic Cr(VI) exposed BEAS-2B cells. Western blot analysis showed that luteolin inhibited multiple gene products linked to survival (Akt, Fak, Bcl-2, Bcl-xL), inflammation (MAPK, NF-κB, COX-2, STAT-3, iNOS, TNF-α) and angiogenesis (HIF-1α, VEGF, MMP-9) in chronic Cr(VI) exposed BEAS-2B cells. Nude mice injected with BEAS-2B cells chronically exposed to Cr(VI) in the presence of luteolin showed reduced tumor incidence compared to Cr(VI) alone treated group. Overexpression of catalase (CAT) or SOD2, eliminated Cr(VI)-induced malignant transformation. Overall, our results indicate that luteolin protects BEAS-2B cells from Cr(VI)-induced carcinogenesis by scavenging ROS and modulating multiple cell signaling mechanisms that are linked to ROS. Luteolin, therefore, serves as a potential chemopreventive agent against Cr(VI)-induced carcinogenesis.

Keywords: Angiogenesis; Carcinogenesis; Hexavalent chromium; Inflammation; Luteolin.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiogenic Proteins / metabolism
  • Animals
  • Anticarcinogenic Agents / pharmacology*
  • Apoptosis Regulatory Proteins / metabolism
  • Bronchi / drug effects*
  • Bronchi / metabolism
  • Bronchi / pathology
  • Cell Line
  • Cell Survival / drug effects
  • Cell Transformation, Neoplastic / chemically induced
  • Cell Transformation, Neoplastic / drug effects*
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / metabolism
  • Cell Transformation, Neoplastic / pathology
  • Chromium / toxicity*
  • Cytoprotection
  • Dose-Response Relationship, Drug
  • Epithelial Cells / drug effects*
  • Epithelial Cells / metabolism
  • Epithelial Cells / pathology
  • Free Radical Scavengers / pharmacology*
  • Humans
  • Inflammation Mediators / metabolism
  • Lung Neoplasms / chemically induced
  • Lung Neoplasms / genetics
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Lung Neoplasms / prevention & control*
  • Luteolin / pharmacology*
  • Mice, Nude
  • Oxidative Stress / drug effects*
  • Potassium Dichromate / toxicity*
  • Reactive Oxygen Species / metabolism*
  • Signal Transduction / drug effects*
  • Transfection
  • Xenograft Model Antitumor Assays

Substances

  • Angiogenic Proteins
  • Anticarcinogenic Agents
  • Apoptosis Regulatory Proteins
  • Free Radical Scavengers
  • Inflammation Mediators
  • Reactive Oxygen Species
  • Chromium
  • chromium hexavalent ion
  • Luteolin
  • Potassium Dichromate